Tools / Targets FDPS: Farnesyl pyrophosphate synthase Key enzyme in isoprenoid biosynthesis which catalyzes the formation of farnesyl diphosphate (FPP), a precursor for several classes of essential metabolites including sterols, dolichols, carotenoids, and ubiquinones.
Drugs that act on it : 6 Approved : 6 In phases 1 to 3 : 0 Sponsors : 4 Who is on it, and how far along Every drug ChEMBL records acting on FDPS, by the furthest stage it has reached for any use, coloured by modality.
How to read this Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
Approved6 Zoledronic acid anhydrous Zoledronic acid anhydrous SponsorNot known ModalitySmall molecule ActionInhibitor Open trials48 Alendronic acid Alendronic acid SponsorOrganon ModalitySmall molecule ActionInhibitor Open trials16 Risedronic acid Risedronic acid SponsorHanlim Pharm ModalitySmall molecule ActionInhibitor Open trials4 Ibandronic acid Ibandronic acid SponsorRoche ModalitySmall molecule ActionInhibitor Open trials2 Minodronic acid Minodronic acid SponsorAstellas Pharma ModalitySmall molecule ActionInhibitor Open trials0 Pamidronic acid Pamidronic acid SponsorNot known ModalitySmall molecule ActionInhibitor Open trials0
Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: Farnesyl diphosphate synthase inhibitor. The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 21 in all, from ClinicalTrials.gov. Trial Drug Phase Status Lead sponsor First posted Fighting Osteoporosis With Risedronate Co-Therapy During Incretin Risedronic acid Phase 3 Not yet recruiting Wake Forest University Health Sciences Nov 17, 2026 Sequential Treatment With Romosozumab Followed by Denosumab vs. Zoledronic Acid for Gains in HIP BMD Zoledronic acid anhydrous Phase 4 Not yet recruiting Sahlgrenska University Hospital Aug 19, 2026 Pharmacokinetics of Zoledronic Acid in Patients on Dialysis Zoledronic acid anhydrous Phase 1 Not yet recruiting University of Campinas, Brazil Aug 3, 2026 Surgery vs. No Surgery for Primary Tumor in De Novo Stage IV Breast Cancer With Solitary Bone Metastases Zoledronic acid anhydrous Not applicable Not yet recruiting West China Hospital Jul 7, 2026 EFFICACY AND SAFETY OF ZOLEDRONATE VERSUS PLACEBO ON PAIN AT WEEK 12 IN PEDIATRIC PATIENTS WITH CHRONIC RECURRENT MULTIFOCAL OSTEOMYELITIS Zoledronic acid anhydrous Phase 2 Not yet recruiting Assistance Publique - Hôpitaux de Paris Jun 25, 2026 Phase Ib Trial of Injectable RAB001 for Knee Osteoarthritis Alendronic acid Phase 1 Enrolling by invitation ZhongShan LaiBo RuiChen BioMedicine Co.,Ltd. Jun 17, 2026 A Phase II Trial of RAB001 (LLP2A-Alendronate) for Steroid-Induced Early-Stage Osteonecrosis of the Femoral Head Alendronic acid Phase 2 Active, not recruiting ZhongShan LaiBo RuiChen BioMedicine Co.,Ltd. Mar 13, 2026 Camrelizumab Plus Risedronate and Chemotherapy for Triple-Negative Breast Cancer: An Exploratory Clinical Study on Mechanisms and Efficacy Risedronic acid Phase 2 Active, not recruiting Harbin Medical University Mar 13, 2026 Zoledronic Acid Treatment in Patients With Congenital Dyserythropoietic Anemia Zoledronic acid anhydrous Phase 1 / Phase 2 Recruiting Institute of Hematology & Blood Diseases Hospital, China Mar 13, 2026 Prospective, Randomized, Multicenter Clinical Trial of Bisphosphonates Combined With Vancomycin for the Treatment of Cierny-Mader Type I and III Osteomyelitis Alendronic acid Phase 3 Recruiting Second Affiliated Hospital, Zhejiang University, School of Medicine Feb 27, 2026 The Comparison of Ibandronate and Zoledronic Acid After Denosumab Discontinuation Ibandronic acid, Zoledronic acid anhydrous Phase 4 Recruiting National Taiwan University Hospital Feb 12, 2026 Zoledronate to Prevent Bone Health Complications in Pediatric Hematopoietic Stem Cell Transplant Survivors Zoledronic acid anhydrous Phase 1 Recruiting Children's Hospital Medical Center, Cincinnati Jan 29, 2026 Step-down Therapy After Long-term Osteoporosis Treatment Zoledronic acid anhydrous Phase 4 Recruiting National Taiwan University Hospital Dec 15, 2025 Alendronate to Reduce Pelvic Insufficiency Fractures in Cervical Cancer Patients Undergoing Chemoradiation Alendronic acid Phase 1 / Phase 2 Not yet recruiting Dr. Itay GoorAryeh Nov 24, 2025 Small Trial of Alendronate Impact on the Reservoir of HIV Alendronic acid Phase 2 Recruiting National Institute of Allergy and Infectious Diseases (NIAID) Oct 15, 2025 Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone Metastases Ibandronic acid Phase 2 Recruiting Kelly Fitzgerald, MD Jun 29, 2025 A Clinical Study on the Effect of Discontinuing Alendronate in Postmenopausal Women With Osteoporosis After a Treatment Period Without Fractures Alendronic acid Phase 4 Recruiting Odense University Hospital Mar 7, 2025 Clinical Efficacy of 1% Metformin and Alendronate Gel in Adjunct to Fibrin in Chronic Periodontitis Alendronic acid Phase 4 Active, not recruiting Bahria University Mar 4, 2025 Precision Medicine Approach for Osteoporosis - Follow Up Study Alendronic acid Phase 4 Enrolling by invitation Paul F Netzel Feb 20, 2024 Bisphosphonate Use to Mitigate Bone Loss Secondary to Bariatric Surgery Risedronic acid Phase 3 Recruiting Wake Forest University Health Sciences Jun 10, 2021 Effects of Bisphosphonates on OI-Related Hearing Loss Risedronic acid Phase 4 Recruiting Hospital for Special Surgery, New York Nov 5, 2019
Show all 21Diseases most associated with it Open Targets association score, 0 to 1; all associations Porokeratosis 9, multiple types 0.64 Porokeratosis 9, multiple types Value0.64 Disseminated superficial actinic porokeratosis 0.62 Disseminated superficial actinic porokeratosis Value0.62 Osteoporosis 0.61 Osteoporosis Value0.61 Open Postmenopausal osteoporosis 0.60 Postmenopausal osteoporosis Value0.60 Open Plasma cell myeloma 0.60 Plasma cell myeloma Value0.60 Bone Paget disease 0.60 Bone Paget disease Value0.60 Prostate carcinoma 0.59 Prostate carcinoma Value0.59 Metastasis 0.59 Metastasis Value0.59 Bone fracture 0.58 Bone fracture Value0.58 Open Prostate cancer 0.57 Prostate cancer Value0.57 Open Hypercalcemia disease 0.56 Hypercalcemia disease Value0.56 Cancer 0.56 Cancer Value0.56 Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL1782 , ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov , checked daily; this page as of 2026-11-21. Gene name, function (UniProt P14324 , CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets